接受Rezūm水蒸气疗法治疗的男性前列腺体积变化与症状改善
本研究评估49例接受Rezūm水蒸气疗法治疗良性前列腺增生的男性,在基线及术后12个月评估生活质量结局与前列腺体积。术后12个月前列腺体积中位变化为-34.0%,45/49(91.8%)患者体积缩小;在体积缩小的45例患者中,体积每缩小10%,国际前列腺症状评分改善7.5%(95%CI 1.4%-13.6%;P=.02);注射总次数或注射次数与基线体积比与前列腺体积变化无显著关联。
要点
- 术后12个月前列腺体积中位缩小34.0%,45/49(91.8%)患者体积缩小。
- 体积缩小的患者中,体积每缩小10%,IPSS改善7.5%(95%CI 1.4%-13.6%;P=.02)。
- 注射总次数或注射次数与基线体积比与前列腺体积变化无显著关联。
核心结论
- 在接受Rezūm疗法治疗良性前列腺增生的男性队列中,前列腺体积缩小越大与症状改善越大相关。
- 本研究显示更多注射次数或注射次数与前列腺体积比与前列腺体积变化无关联,反驳了注射越多越好的说法。
研究设计与样本
- 评估接受Rezūm疗法治疗男性前列腺体积变化及其与泌尿症状评分改善关系的研究。
- 共49例男性(平均年龄67.8岁;标准差9.4)于2019年4月至2020年9月间接受该手术。
- 在基线和术后12个月评估生活质量结局和前列腺体积,计算结局和前列腺体积相对基线的百分比变化以及Rezūm注射次数与基线前列腺体积比。
- 使用线性回归模型评估注射总次数与结局变化及前列腺体积变化之间的关联。
主要发现
- 基线前列腺体积中位数为71.5 cc(范围24-150),中位蒸汽注射次数为11.0次(范围4-21)。
- 术后12个月前列腺体积中位百分比变化为-34.0%(四分位距:-49.2%,-16.7%),45/49(91.8%)患者体积缩小。
- 在45例术后12个月体积缩小的患者中,体积每缩小10%与国际前列腺症状评分改善7.5%相关(95%CI 1.4%-13.6%;P=.02)。
- 注射总次数或注射次数与基线体积比与前列腺体积变化之间无显著关联。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To evaluate the change in prostate volume (PV) and relationship to improvement in urinary symptom scores following Rezūm therapy. METHODS: Quality of life outcomes and PV were assessed at baseline and 12months postprocedure. Percent change from baseline in outcomes and PV were calculated, as was the number of Rezum injection to baseline PV ratio. Association between total number of injections and changes in outcomes and PV were evaluated using linear regression models. RESULTS: A total of 49 men (mean age=67.8; standard deviation=9.4) underwent the procedure between April 2019 and September 2020, with a median baseline PV of 71.5 cc (range 24-150) and median number of vapor injections of 11.0 (range 4-21). At 12months, the median percent change in PV was - 34.0% (interquartile range: -49.2%, -16.7%), with 45/49 (91.8%) patients having reduced volume. Among the 45 patients with reduced volume at 12months, every 10% increase in volume reduction was associated with a 7.5% (95% confidence interval, 1.4%-13.6%; P = .02) improvement in the International Prostate Symptom Score. There was no significant association between total number of injections or injection to baseline volume ratio and change in PV. CONCLUSION: In this cohort of men treated with Rezūm therapy for benign prostatic hyperplasia, it was demonstrated that there is a correlation between greater PV reduction and greater symptomatic improvement. This study showed no association between more injections or the ratio of injections to PV changes, refuting the claim that more injections are better.
引用
- Elterman D, Bhojani N, Chughtai B, et al. Change in Prostate Volume and Symptom Improvement in Men Treated With Rezūm Water Vapor Therapy. Urology. 2023. PMID: 37076022. doi:10.1016/j.urology.2023.04.008
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。